Aug 29, 2016 7:03 am EDT Abeona Therapeutics Completes Enrollment of Low-Dose Cohort for ABO-102 in Phase 1/2 Clinical Trial for MPS IIIA Patients
Aug 16, 2016 7:03 am EDT Abeona Therapeutics Announces Second Quarter 2016 Financial Results and Recent Clinical Highlights
Aug 9, 2016 7:03 am EDT Abeona Therapeutics, EB Research Partnership and EB Medical Research Foundation to Collaborate on Epidermolysis Bullosa (EB) Treatments
Aug 4, 2016 7:03 am EDT Abeona Therapeutics Announces European Regulatory Approval for Phase 1/2 Gene Therapy Clinical Study for Patients With Sanfilippo Syndrome Type A (MPS IIIA)
Aug 2, 2016 7:03 am EDT Abeona Therapeutics Provides Update on Initial Subjects in Sanfilippo Type A Gene Therapy Trial, Demonstrating Encouraging Early Biopotency Signals
Jun 30, 2016 7:03 am EDT Abeona Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
Jun 7, 2016 7:03 am EDT Abeona Therapeutics to Present at Jefferies 2016 Global Healthcare Conference
May 24, 2016 7:03 am EDT Abeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Phase 1/2 Clinical Study With ABO-101 Gene Therapy for Patients With Sanfilippo Syndrome Type B (MPS IIIB)
